大剂量阿糖胞苷巩固治疗急性髓细胞白血病后无病生存分析

目的：探讨大剂量阿糖胞苷（HDAra—C）对急性髓细胞白血病（AML）缓解后巩固治疗的无病生存（DFS）影响。方法：以阿糖胞苷3g，静滴2～3h，q12h，连续应用6个剂量为1疗程，共用5疗程。结果：中位完全缓解期为13．5（3～167）个月，中位DFS为17．5（3～167）个月，中位总生存为22．5（7～169）个月。3年和5年的DFS率分别为54％和42％。3年和5年OS率分别为68％和49％。结论：HDAra—C用于AML的缓解后巩固治疗，可望缩短化疗时间，提高无病生存率，改善牛活质量，且患者能耐受治疗中所出现的不良反应。

An analysis on effect of consolidation therapy with high-dose cytarabine on prolonging disease-free survival in acute myelogenous leukemia

Objective:To investigate the effect of high dose cytarabine (HDAra-C)on long-term disease-free survival as postremission consolidation therapy in acute myeloid leukemia (AML).Method:Cytarabine of 3g was intravenously infused lasted for 2~3 hrs, and once per 12 hrs for consecutive 6 dosages were considered as a course. The therapy with total 5 courses was completed in all subjects.Result:After consolidation therapy, the median duration of complete remission was 13.5(3~167) months; the median of the disease-free survive (DFS) was 17.5(3~167) months; and overall survival (OS) was 22.5(7~169) months. The expectation of DFS at 3 and 5 years was 54% and 42% respectively. And, OS at 3 and 5 year was 68% and 49% respectively.Conclusion:The postremission consolidation chemotherapy with HDAra-C can prolong DFS and improve the quality of life, and cause a few tolerated side effects.